Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration

Richard F. Spaide, Ketan Laud, Howard F. Fine, James M. Klancnik, Catherine Meyerle, Lawrence A. Yannuzzi, John Sorenson, Jason Slakter, Yale L. Fisher, Michael J. Cooney

Research output: Contribution to journalArticle

Abstract

PURPOSE: To describe the short-term anatomical and visual acuity responses after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We conducted a retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab (1.25 mg) during a 3-month period. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4%). The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7%) had inadequate response to alternate methods of treatment. At the 1-month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (P <0.001 as compared with baseline), and 74 (30.3%) of patients had improvement in visual acuity as defined by a halving of the visual angle. At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (P <0.001), and 78 (31.1%) of patients had visual improvement. At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (P <0.001), and 54 (38.3%) of patients had visual acuity improvement. The mean central macular thickness at baseline was 340 μm and decreased to a mean of 247 μm at month 1 (P <0.001) and 213 μm at month 3 (P <0.001). At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis. No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred. The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration. CONCLUSION: There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Original languageEnglish (US)
Pages (from-to)383-390
Number of pages8
JournalRetina
Volume26
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Visual Acuity
Intravitreal Injections
Therapeutics
Bevacizumab
Retinal Perforations
Endophthalmitis
Uveitis
Optical Coherence Tomography
Retinal Detachment
Intraocular Pressure

Keywords

  • Age-related macular degeneration
  • Bevacizumab
  • Choroidal neovascularization
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Spaide, R. F., Laud, K., Fine, H. F., Klancnik, J. M., Meyerle, C., Yannuzzi, L. A., ... Cooney, M. J. (2006). Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina, 26(4), 383-390. https://doi.org/10.1097/00006982-200604000-00001

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. / Spaide, Richard F.; Laud, Ketan; Fine, Howard F.; Klancnik, James M.; Meyerle, Catherine; Yannuzzi, Lawrence A.; Sorenson, John; Slakter, Jason; Fisher, Yale L.; Cooney, Michael J.

In: Retina, Vol. 26, No. 4, 04.2006, p. 383-390.

Research output: Contribution to journalArticle

Spaide, RF, Laud, K, Fine, HF, Klancnik, JM, Meyerle, C, Yannuzzi, LA, Sorenson, J, Slakter, J, Fisher, YL & Cooney, MJ 2006, 'Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration', Retina, vol. 26, no. 4, pp. 383-390. https://doi.org/10.1097/00006982-200604000-00001
Spaide, Richard F. ; Laud, Ketan ; Fine, Howard F. ; Klancnik, James M. ; Meyerle, Catherine ; Yannuzzi, Lawrence A. ; Sorenson, John ; Slakter, Jason ; Fisher, Yale L. ; Cooney, Michael J. / Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. In: Retina. 2006 ; Vol. 26, No. 4. pp. 383-390.
@article{e734acb54d2348deb4151153c60f71f0,
title = "Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration",
abstract = "PURPOSE: To describe the short-term anatomical and visual acuity responses after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We conducted a retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab (1.25 mg) during a 3-month period. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4{\%}). The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7{\%}) had inadequate response to alternate methods of treatment. At the 1-month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (P <0.001 as compared with baseline), and 74 (30.3{\%}) of patients had improvement in visual acuity as defined by a halving of the visual angle. At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (P <0.001), and 78 (31.1{\%}) of patients had visual improvement. At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (P <0.001), and 54 (38.3{\%}) of patients had visual acuity improvement. The mean central macular thickness at baseline was 340 μm and decreased to a mean of 247 μm at month 1 (P <0.001) and 213 μm at month 3 (P <0.001). At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis. No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred. The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration. CONCLUSION: There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.",
keywords = "Age-related macular degeneration, Bevacizumab, Choroidal neovascularization, Vascular endothelial growth factor",
author = "Spaide, {Richard F.} and Ketan Laud and Fine, {Howard F.} and Klancnik, {James M.} and Catherine Meyerle and Yannuzzi, {Lawrence A.} and John Sorenson and Jason Slakter and Fisher, {Yale L.} and Cooney, {Michael J.}",
year = "2006",
month = "4",
doi = "10.1097/00006982-200604000-00001",
language = "English (US)",
volume = "26",
pages = "383--390",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration

AU - Spaide, Richard F.

AU - Laud, Ketan

AU - Fine, Howard F.

AU - Klancnik, James M.

AU - Meyerle, Catherine

AU - Yannuzzi, Lawrence A.

AU - Sorenson, John

AU - Slakter, Jason

AU - Fisher, Yale L.

AU - Cooney, Michael J.

PY - 2006/4

Y1 - 2006/4

N2 - PURPOSE: To describe the short-term anatomical and visual acuity responses after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We conducted a retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab (1.25 mg) during a 3-month period. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4%). The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7%) had inadequate response to alternate methods of treatment. At the 1-month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (P <0.001 as compared with baseline), and 74 (30.3%) of patients had improvement in visual acuity as defined by a halving of the visual angle. At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (P <0.001), and 78 (31.1%) of patients had visual improvement. At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (P <0.001), and 54 (38.3%) of patients had visual acuity improvement. The mean central macular thickness at baseline was 340 μm and decreased to a mean of 247 μm at month 1 (P <0.001) and 213 μm at month 3 (P <0.001). At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis. No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred. The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration. CONCLUSION: There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

AB - PURPOSE: To describe the short-term anatomical and visual acuity responses after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: We conducted a retrospective study of patients with CNV secondary to AMD who were treated with intravitreal injection of bevacizumab (1.25 mg) during a 3-month period. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4%). The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7%) had inadequate response to alternate methods of treatment. At the 1-month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (P <0.001 as compared with baseline), and 74 (30.3%) of patients had improvement in visual acuity as defined by a halving of the visual angle. At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (P <0.001), and 78 (31.1%) of patients had visual improvement. At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (P <0.001), and 54 (38.3%) of patients had visual acuity improvement. The mean central macular thickness at baseline was 340 μm and decreased to a mean of 247 μm at month 1 (P <0.001) and 213 μm at month 3 (P <0.001). At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis. No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred. The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration. CONCLUSION: There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

KW - Age-related macular degeneration

KW - Bevacizumab

KW - Choroidal neovascularization

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33745091547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745091547&partnerID=8YFLogxK

U2 - 10.1097/00006982-200604000-00001

DO - 10.1097/00006982-200604000-00001

M3 - Article

C2 - 16603955

AN - SCOPUS:33745091547

VL - 26

SP - 383

EP - 390

JO - Retina

JF - Retina

SN - 0275-004X

IS - 4

ER -